AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
23rd July 2021 Uncategorised 0AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says nhigginsdunn Fri, 07/23/2021 – 14:46 More: AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says Source: fierce
read more